ProMIS Neurosciences Stock Price, News & Analysis (NASDAQ:PMN) $1.15 -0.01 (-0.86%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$1.15▼$1.1950-Day Range$1.15▼$2.0052-Week Range$1.06▼$8.95Volume3,572 shsAverage Volume13,986 shsMarket Capitalization$21.72 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ProMIS Neurosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside595.7% Upside$8.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.36) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector831st out of 932 stocksPharmaceutical Preparations Industry389th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingProMIS Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, ProMIS Neurosciences has a forecasted upside of 595.7% from its current price of $1.15.Amount of Analyst CoverageProMIS Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PMN. Previous Next 0.0 Dividend Strength Dividend YieldProMIS Neurosciences does not currently pay a dividend.Dividend GrowthProMIS Neurosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for ProMIS Neurosciences this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added ProMIS Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProMIS Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.30% of the stock of ProMIS Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.18% of the stock of ProMIS Neurosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProMIS Neurosciences are expected to grow in the coming year, from ($1.36) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProMIS Neurosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProMIS Neurosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ProMIS Neurosciences Stock (NASDAQ:PMN)ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More PMN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMN Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comProMIS Neurosciences (NASDAQ:PMN) Trading Up 0.7%November 14, 2023 | msn.comProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14December 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.September 6, 2023 | finance.yahoo.comProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | msn.comProMIS Neurosciences scales 31% on $20.4M private placementAugust 21, 2023 | finance.yahoo.comProMIS Neurosciences Announces $20.4 Million Private Placement FinancingMay 15, 2023 | finance.yahoo.comProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsMay 6, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Friday (PMN)December 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comApril 27, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)April 25, 2023 | finance.yahoo.comData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseApril 24, 2023 | finance.yahoo.comProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingApril 19, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)April 18, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Monday (PMN)April 15, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Friday (PMN)April 10, 2023 | proactiveinvestors.comProMIS Neurosciences submits IND application for Alzheimer's treatmentSee More Headlines Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PMN CUSIPN/A CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+595.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,060,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-219.98% Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.81 Sales & Book Value Annual Sales$10,000.00 Price / Sales2,172.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-7.19Miscellaneous Outstanding Shares18,890,000Free Float16,940,000Market Cap$21.72 million OptionableNot Optionable Beta0.53 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Eugene Williams (Age 64)Co-Founder & Chairman Comp: $439.21kDr. Gail M. Farfel Ph.D. (Age 59)CEO & Director Comp: $177.23kDr. Neil R. Cashman M.D. (Age 71)Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director Comp: $333.8kMr. Gavin T. Malenfant (Age 59)Chief Operating Officer Comp: $413.49kMr. Daniel E. Geffken M.B.A. (Age 66)Chief Financial Officer Comp: $90.57kDr. Johanne Kaplan Ph.D. (Age 63)Chief Development Officer Comp: $264.77kDr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Senior ConsultantDr. David Wishart Ph.D.Chief Physics OfficerMr. Dennis Chen Ph.D.Head of Manufacturing & Senior ConsultantDr. Larry Douglas Altstiel M.D. (Age 73)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMNRx PharmaceuticalsNASDAQ:NRXPSurrozenNASDAQ:SRZNBioCardiaNASDAQ:BCDAAlterity TherapeuticsNASDAQ:ATHEView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 265,958 shares on 11/15/2023Ownership: 3.100%View All Institutional Transactions PMN Stock Analysis - Frequently Asked Questions Should I buy or sell ProMIS Neurosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMN shares. View PMN analyst ratings or view top-rated stocks. What is ProMIS Neurosciences' stock price target for 2024? 2 brokerages have issued 12-month target prices for ProMIS Neurosciences' shares. Their PMN share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 595.7% from the stock's current price. View analysts price targets for PMN or view top-rated stocks among Wall Street analysts. How have PMN shares performed in 2023? ProMIS Neurosciences' stock was trading at $4.34 on January 1st, 2023. Since then, PMN shares have decreased by 73.5% and is now trading at $1.15. View the best growth stocks for 2023 here. When is ProMIS Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our PMN earnings forecast. How were ProMIS Neurosciences' earnings last quarter? ProMIS Neurosciences, Inc. (NASDAQ:PMN) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.19) earnings per share for the quarter. Who are ProMIS Neurosciences' major shareholders? ProMIS Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (3.10%). How do I buy shares of ProMIS Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PMN) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.